Lexicon Pharmaceuticals (LXRX) Common Equity (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Common Equity data on file, last reported at $202.9 million in Q1 2026.

• On a quarterly basis, Common Equity rose 64.88% year-over-year to $202.9 million in Q1 2026; TTM through Mar 2026 was $202.9 million, a 64.88% increase from a year earlier, with the FY2025 full-year figure at $107.5 million, down 26.32% from the prior year.
• Common Equity for Q1 2026 stood at $202.9 million, up from $107.5 million in the prior quarter.
• Over the last five years, Common Equity for LXRX reached as high as $288.9 million in Q1 2024 and fell as low as $70.8 million in Q2 2022.
• Historically, Common Equity has averaged $145.2 million across 5 years, with a median of $129.4 million in 2025.
• Across the five-year window, Common Equity surged 228.09% in 2024 and tumbled 57.41% in 2025, its largest moves.
• Year by year, Common Equity stood at $117.1 million in 2022, then declined by 20.5% to $93.1 million in 2023, then surged by 56.75% to $146.0 million in 2024, then declined by 26.32% to $107.5 million in 2025, then jumped by 88.64% to $202.9 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $202.9 million in Q1 2026, $107.5 million in Q4 2025, and $120.2 million in Q3 2025.